The 100% natural formulation is said to be extensively backed by over 55 published studies worldwide and several ongoing studies for its therapeutic activity on multiple health indications, making it unparalleled in the segment.

The formulation is already protected by 49 patents (14 in the US, two in Japan and 33 in European countries) for composition and manufacturing processes of curcumin extract.

“The composition of BCM-95 (Curcugreen) contains only turmeric based components and no synthetic or non-turmeric ingredients,” said Benny Antony, Joint Managing Director for Arjuna. “This composition of turmeric delivers free curcumin into blood and is retained in the body for longer duration.”

Arjuna says that this patent in effect helps to address much confusion in the market regarding curcumin absorption and oral bioavailability. The main problem of curcumin, the company claims, is that it is not absorbed nor retained well in the blood streams - yet the market has subsequently been flooded with curcumin products laden with synthetic additives in attempts to overcome the issue of bioavailability. Also, Arjuna claims, it is observed that many brands are toll manufactured at production centers not complying to cGMP standards.

“Any supplement you put into your body should be both safe and effective,” said Antony. “Arjuna’s BCM-95 (Curcugreen) is wholly manufactured in its own facility under a fully automated cGMP complied continuous extraction plant—using only solar power. This has enabled Arjuna to triple its manufacturing capacity in Coimbatore, India to meet the growing demand for their brand of curcumin in the coming years.”

According to the company, the success of BCM-95 (Curcugreen) has enabled Arjuna to rev up its marketing activities and cement its foothold in the European market as well as in the USA.

“With the mobilization of our dedicated sales force we hope to increase our market reach significantly in the coming years,” said P.J Kunjachan, Chairman & Managing Director.